Tennessee is currently home to 1990 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)
NCT05268094
Recruiting
COMPASS is a prospective multicenter randomized interventional trial. Participants with ductal-dependent pulmonary blood flow will be randomized to receive either a systemic-to-pulmonary artery shunt or ductal artery stent. Block randomization will be performed by center and by single vs. two ventricle status. Participants will be followed through the first year of life.
Gender:
All
Ages:
Between 1 day and 30 days
Trial Updated:
04/12/2023
Locations: Le Bonheur Children's Hospital, Memphis, Tennessee
Conditions: Congenital Heart Disease in Children
Register for Updates
Screening for High Frequency Malignant Disease
NCT05117840
Recruiting
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/10/2023
Locations: The Jackson Clinic, Jackson, Tennessee
Conditions: Lung Cancer
Register for Updates
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
NCT05064358
Recruiting
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2023
Locations: GSK Investigational Site, Chattanooga, Tennessee
Conditions: Multiple Myeloma
Register for Updates
Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
NCT05798897
Recruiting
This study is a Phase 1multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory NHL. The dose administered is 200 x 10^6 cells (flat dosing).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/04/2023
Locations: Tennessee Oncology PLLC, Nashville, Tennessee
Conditions: Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma
Register for Updates
Study to Evaluate the Reliability, Validity and Safety of Subjective Mobile Refraction
NCT05049070
Recruiting
This study evaluates the reliability, validity and safety of a self administered, subjective refraction test via a mobile medical app (GoEyes) as compared to standard of care subjective manifest refraction performed by a health care provider, in subjects who have no known ocular disease or condition other than refractive error.
Gender:
All
Ages:
Between 18 years and 39 years
Trial Updated:
04/04/2023
Locations: Total Eye Care, Memphis, Tennessee
Conditions: Refractive Errors
Register for Updates
The Hancock Jaffe Surgical Antireflux Venous Valve Endoprosthesis Study
NCT04943172
Recruiting
A prospective, non blinded, single arm, multicenter study designed to assess the safety and effectiveness of the bioprosthetic, VenoValve, which is surgically implanted into the deep venous system for treatment of patients with deep venous valvular insufficiency ( C4b-C6 patients).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Deep Venous Insufficiency (Diagnosis)
Register for Updates
Auditory Neural Function in Implanted Patients With Usher Syndrome
NCT04906135
Recruiting
Usher syndrome (USH) causes extensive degeneration in the cochlear nerve (CN), especially in CN fibers innervating the base of the cochlea. As the first step toward developing evidence-based practice for managing implant patients with USH, this study evaluates local neural health, as well as the neural encoding of temporal and spectral cues at the CN in implanted patients with USH. Aim 1 will determine local CN health in patients with USH by assessing the sensitivity of the electrically evoked c... Read More
Gender:
All
Ages:
Between 1 year and 85 years
Trial Updated:
04/03/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Usher Syndrome, Cochlear Implantation
Register for Updates
Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
NCT00178932
Recruiting
The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/03/2023
Locations: Psychiatric Hospital at Vanderbilt, Nashville, Tennessee
Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Register for Updates
Mechanically Optimizing Cardiac Preload in Heart Failure Patients
NCT04338503
Recruiting
The purpose of the current study is to determine if partial balloon occlusion of the inferior vena cava can optimize cardiac pre-load and subsequently pulmonary pressures and cardiac output as a novel method to unload pulmonary edema and other symptoms of decompensated congestive heart failure. All products in this study are FDA approved and adhere to the specifications of the intended use.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/28/2023
Locations: Saint Thomas Heart, Nashville, Tennessee
Conditions: Heart Failure
Register for Updates
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
NCT04053673
Recruiting
RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the cell from sending a signal (Type 1 interferon) that tells the immune system that something is wrong and to kill the cell. RBN-2397 has been shown in animal studies to inhibit tumor growth and also shuts down the "don't kill me" signal the tumor is sending to evade the immune system. As a PARP7 inhibitor RBN-2397 is... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: SCRI-Nashville/Tennessee Oncology, Nashville, Tennessee
Conditions: Solid Tumor, Adult
Register for Updates
Delirium Reduction With Ramelteon
NCT05069428
Recruiting
The overall purpose of this study is to identify a medication that might treat and/or prevent delirium in intensive care unit (ICU). Currently, there is no proven medical therapy for prevention or treatment of delirium. Ramelteon is a medication approved for insomnia. We hypothesize that ramelteon may help regulate the day/night cycle and decrease ICU delirium.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2023
Locations: Centennial Medical Center, Nashville, Tennessee
Conditions: Delirium
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).
Gender:
All
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Langerhans Cell Histiocytosis
Register for Updates